Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02739984 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
A Phase 3 study of Type 2 Diabetes and Hypercholesterolemia, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 424
- Enrollment target
- 20
- Study locations
NCT02739984: Completed Phase 3 study of Type 2 Diabetes and Hypercholesterolemia, sponsored by Amgen.
NCT02739984 is a Phase 3 study of Type 2 Diabetes and Hypercholesterolemia that has completed, run by Amgen. The registered enrollment target is 424 participants, below the 3,922-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02739984, a Phase 3 study of Type 2 Diabetes and Hypercholesterolemia, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 424 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in adults with type 2 diabetes mellitus and high blood cholesterol on a maximally tolerated oral dose of statin of at least moderate-intensity.
Conditions Studied
Interventions
- BIOLOGICAL Evolocumab
- DRUG Placebo to Evolocumab
Study Locations (20)
Florida
- Research Site - Boca Raton
- Research Site - Coral Gables
- Research Site - Daytona Beach
- Research Site - Fleming Island
- Research Site - Hollywood
- Research Site - Inverness
- Research Site - Jacksonville
- Research Site - Miami
California
- Research Site - Lomita
- Research Site - Los Angeles
- Research Site - Roseville
- Research Site - San Ramon
- Research Site - Spring Valley
- Research Site - Tarzana
- Research Site - Walnut Creek
Colorado
- Research Site - Denver
- Research Site - Lakewood
Alabama
- Research Site - Tuscumbia
Arizona
- Research Site - Phoenix
Delaware
- Research Site - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2016-05-17 |
| Est. Completion | 2017-08-03 |
| Phase | Phase 3 |
What the finished NCT02739984 record still lists
NCT02739984 is an interventional study that assigns participants to a tested intervention. The registered 424 participants enrollment target is mid-sized for trials with a published cap, below the 3,922-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Evolocumab is the first listed.
NCT02739984 names 20 study sites across 6 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02739984 about?
NCT02739984 is a clinical study titled "Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia". The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in adults with type 2 diabetes mellitus and high blood cholesterol on a maximally tolerated oral do...
What is the current status of trial NCT02739984?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 424 participants. The study started on 2016-05-17. Estimated completion is 2017-08-03.
What conditions does trial NCT02739984 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Hypercholesterolemia, Mixed Dyslipidemia.
What interventions are being tested in trial NCT02739984?
The interventions under investigation include: Evolocumab (BIOLOGICAL), Placebo to Evolocumab (DRUG).
Who is sponsoring clinical trial NCT02739984?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02739984 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02739984's enrollment target sits among peer trials
424 50th of 327 higher than 278 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
- NCT06978127 · 424 participants · NA
Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients
- NCT07140913 · 424 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI